The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.

Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.

AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.

Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.

Immunology firm, INmune Bio, Inc. will present its findings on the use of INB03 in managing high-risk MUC4 expressing HER2+ breast cancer. INB03 is a dominant-negative suppressor of soluble TNF.

Sarepta Therapeutics, Inc. shared initial results from EMBARK, a global Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in Duchenne muscular dystrophy patients aged 4-7.

SparX Biopharmaceutical Corp. happily announces FDA approval of its IND application for SPX-303, a key development in powered antibody therapies and a leading anti-LILRB2/PD-L1 bispecific antibody drug candidate.

Volastra Therapeutics has begun dosing the first participant in a Phase I/II clinical trial of VLS-1488, which, along with sovilnesib, forms their portfolio of unique KIF18A inhibitors designed to treat solid tumors with high chromosomal instability.

At the 16th Clinical Trials on Alzheimer's Disease convention in Boston on October 27, 2023, clinical-phase biotech firm Allyx Therapeutics revealed findings from their Phase 1a study of ALX-001, their orally administered, pioneering, highly-selective, synapse-focused, disease-modifying neurodegenerative treatment.